NASDAQ:ABUS

Arbutus Biopharma - ABUS Stock Forecast, Price & News

$1.91

-0.07 (-3.54%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.91
▼
$2.04
50-Day Range: $1.88
▼
$2.54
52-Week Range: $1.85
▼
$6.50

Volume: 752,982 shs
Average Volume: 698,889 shs
Market Capitalization: $286.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.13

Arbutus Biopharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 273.0% Upside
$7.13 Price Target
Short Interest: Healthy
2.55% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.59
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.44) to ($0.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

867th out of 1,093 stocks

Pharmaceutical Preparations Industry

426th out of 547 stocks

3.5

Analyst's Opinion

Consensus Rating
Arbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.13, Arbutus Biopharma has a forecasted upside of 273.0% from its current price of $1.91.
Amount of Analyst Coverage
Arbutus Biopharma has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.55% of the outstanding shares of Arbutus Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Arbutus Biopharma has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Arbutus Biopharma has recently decreased by 2.55%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Arbutus Biopharma does not currently pay a dividend.
Dividend Growth
Arbutus Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABUS.

3.1

News and Social Media Coverage

News Sentiment
Arbutus Biopharma has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Arbutus Biopharma this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Arbutus Biopharma is held by insiders.
Percentage Held by Institutions
Only 29.63% of the stock of Arbutus Biopharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.44) to ($0.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arbutus Biopharma is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arbutus Biopharma is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arbutus Biopharma has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arbutus Biopharma (NASDAQ:ABUS) Stock

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

September 30, 2022 | finance.yahoo.com

Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End

September 22, 2022 | finance.yahoo.com

Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 21, 2022 | americanbankingnews.com

Arbutus Biopharma Co. (NASDAQ:ABUS) Sees Large Drop in Short Interest

September 12, 2022 | seekingalpha.com

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

September 6, 2022 | finance.yahoo.com

Arbutus to Participate in September Investor Conferences

September 1, 2022 | finance.yahoo.com

Bucks County biopharm firm issued key patent in pursuit of hepatitis B cure

August 30, 2022 | finance.yahoo.com

Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729

August 10, 2022 | finance.yahoo.com

Analysts Just Shipped A Dazzling Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Estimates

August 8, 2022 | nasdaq.com

Bullish: Analysts Just Made A Noticeable Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Forecasts

August 5, 2022 | finance.yahoo.com

Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript

August 4, 2022 | seekingalpha.com

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 21, 2022 | finance.yahoo.com

Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

July 6, 2022 | finance.yahoo.com

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

June 28, 2022 | finance.yahoo.com

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B

June 25, 2022 | finance.yahoo.com

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update

June 25, 2022 | finance.yahoo.com

Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update

June 8, 2022 | finance.yahoo.com

Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022

June 6, 2022 | finance.yahoo.com

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

June 6, 2022 | seekingalpha.com

Arbutus and Vaccitech begin trial testing combo therapy for chronic hepatitis B virus treatment

June 2, 2022 | finance.yahoo.com

Arbutus to Participate in June Investor Conferences

May 26, 2022 | finance.yahoo.com

Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 17, 2022 | finance.yahoo.com

Arbutus to Present at H.C. Wainwright Global Investment Conference

May 7, 2022 | finance.yahoo.com

Party Time: Brokers Just Made Major Increases To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Earnings Forecasts

May 5, 2022 | nasdaq.com

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Company Calendar

Last Earnings: 8/04/2022
Today: 10/01/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ABUS
CUSIP: N/A
CIK: 1447028
Web: www.arbutusbio.com
Phone: (267) 469-0914
Fax: 604-419-3201
Employees: 85
Year Founded: 1992

Price Target and Rating

Average Stock Price Forecast: $7.13
High Stock Price Forecast: $9.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +273.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,250,000.00
Net Margins: -211.09%
Pretax Margin: -197.77%
Return on Equity: -61.57%
Return on Assets: -34.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.29
Quick Ratio: 5.29

Sales & Book Value

Annual Sales: $10.99 million
Price / Sales: 26.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.17 per share
Price / Book: 1.63

Miscellaneous

Outstanding Shares: 149,950,000
Free Float: 142,154,000
Market Cap: $286.40 million
Optionable: Optionable
Beta: 2.24

Social Links

Key Executives

Mr. William H. Collier (Age 62)
Pres, CEO & Director
Comp: $1.03M

Mr. David C. Hastings CPA (Age 61)
CFO & Chief Accounting Officer
Comp: $647.1k

Dr. Michael J. Sofia Ph.D. (Age 64)
Chief Scientific Officer
Comp: $670.22k

Ms. Lisa M. Caperelli
VP of Investor Relations

Dr. Elizabeth Howard (Age 68)
Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.

Dr. Gaston Picchio Ph.D. (Age 58)
Chief Devel. Officer

Mr. Michael J. McElhaugh (Age 47)
Chief Bus. Officer

Mr. R. Hector Mackay-Dunn B.A. (Age 71)
J.D., L.L.B., Q.C, Q.C., Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABUS Stock - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings or view top-rated stocks.
What is Arbutus Biopharma's stock price forecast for 2022?: 4 brokers have issued 12 month price targets for Arbutus Biopharma's stock. Their ABUS share price forecasts range from $5.00 to $9.00. On average, they predict the company's share price to reach $7.13 in the next year. This suggests a possible upside of 273.0% from the stock's current price.
View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts.
How have ABUS shares performed in 2022?: Arbutus Biopharma's stock was trading at $3.89 at the beginning of 2022. Since then, ABUS stock has decreased by 50.9% and is now trading at $1.91.
View the best growth stocks for 2022 here.
When is Arbutus Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ABUS earnings forecast.
How were Arbutus Biopharma's earnings last quarter?: Arbutus Biopharma Co. (NASDAQ:ABUS) announced its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Arbutus Biopharma had a negative net margin of 211.09% and a negative trailing twelve-month return on equity of 61.57%. During the same period last year, the business earned ($0.23) EPS.

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?: 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Arbutus Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).
What is Arbutus Biopharma's stock symbol?: Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."
How do I buy shares of Arbutus Biopharma?: Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arbutus Biopharma's stock price today?: One share of ABUS stock can currently be purchased for approximately $1.91.
How much money does Arbutus Biopharma make?: Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $286.41 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76,250,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.
How can I contact Arbutus Biopharma?: Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.

This page (NASDAQ:ABUS) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arbutus Biopharma - ABUS Stock Forecast, Price & News

Arbutus Biopharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month